To prevent endometrial hyperplasia in postmenopausal women with an intact uterus receiving conjugated estrogens. Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance without organic pathology.
Medroxyprogesterone acetate (MPA) administered orally or parenterally in the recommended doses to women with adequate endogenous estrogen, transforms proliferative into secretory endometrium. Androgenic and anabolic effects have been noted, but the drug is apparently devoid of significant estrogenic activity. While parenterally administered MPA inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation, available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses.
ORAL Menorrhagia: Adult: 2.5-10 mg daily for 5-10 days starting on the 16th-21st day of the menstrual cycle. Repeat for 2 cycles. Mild to moderate endometrlosis: Adult: 10 mg tid. As progestogen component in menopausal hormonal replacement therapy: Adult: Dosage dependant on oestrogen component of therapy, several regimens are used: 1.5 mg, 2.5 mg or 5 mg daily; 5 or 10 mg daily for 12-14 days of a 28-day cycle; 20 mg daily for 14 days of a 91-day cycle. Breast cancer: Adult: 0.4-1.5 g daily. Max: 2 g daily. Palliative treatment of endometrial & renal carcinoma: Adult: 200-600 mg daily. Secondary amenorrhoea: Adult: 2.5-10 mg daily for 5-10 days. Repeated for 3 cycles. Palliative treatment of prostatic carcinoma: Adult: 100-600 mg daily. INTRAMUSCULAR Endometriosis: Adult: 50 mg wkly or 100mg every 2wk. Contraception: Adult: 150 mg every 12wk. Breast cancer: Adult: 0.5-1 g daily for 1st 4 wk. Maintenance 0.5 g twice wkly. Palliative treatment of endometrial & renal carcinoma: Adult: InItially 0.4-1 g wkly. Reduce as necessary, maintenance may be as low as 0.4 g mthly. Palliative treatment of prostatic carcinoma: Adult: 0.5 g twice wkly for 1st 3 mth. Maintenance 0.5 g wkly. SUBCUTANEOUS Contraception;Endometriosis: Adult: 104 mg every 12-14wk.
Thromboembolic disorders; cerebral apoplexy; severe hepatic dysfunction; undiagnosed vag bleeding, incomplete abortion, hormone-dependent carcinoma; pregnancy. Patients w/ depression, DM, epilepsy. asthma, migraine, hypertension, renal or cardiac dysfunction. Monitor patient closely for loss of vision, proptosis, diplopia & thromboembolic disorders. Lactation.
Depression, fluid retention, Fatigue, insomnia, dizziness, headache, nausea; breast tenderness; wt gain/loss, anorexia; cholestatic jaundice; pain at lnj site. Thrombophlebitis & pulmonary embolism.
Not safe for pregnant women. If taken in the first four months of pregnancy, medroXyprogesterone acetate has been shown to cause minor birth defects. Additionally, it is not safe to take it if you are breastfeeding either, as it is passed through breast milk.
Overdosage of estrogen plus progestin therapy may cause nausea and vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of CE plus MPA together with institution of appropriate symptomatic care.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)